Graham Capital Management’s Pacific Biosciences PACB Stock Holding History

Graham Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.7K	Sell	42,179 -146,306	-78%	-$262K	﹤0.01%	1087
2025 Q4	$352K	Buy	+188,485	New	+$362K	0.01%	784
2022 Q3	–	Sell	-134,862	Closed	-$596K	–	1249
2022 Q2	$596K	Buy	+134,862	New	+$819K	0.02%	612
2022 Q1	–	Sell	-16,475	Closed	-$337K	–	993
2021 Q4	$337K	Sell	16,475 -15,000	-48%	-$362K	0.01%	278
2021 Q3	$804K	Sell	31,475 -8,419	-21%	-$249K	0.04%	98
2021 Q2	$1.4M	Sell	39,894 -4,982	-11%	-$145K	0.07%	103
2021 Q1	$1.49M	Buy	+44,876	New	+$1.57M	0.07%	119

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Graham Capital Management's PACB Position: Q1 2026 in Review

Graham Capital Management reduced its Pacific Biosciences (PACB) stake by 78% in Q1 2026, selling an estimated $262K and leaving 42,179 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Graham Capital Management first reported a position in PACB in Q1 2021 and has held it in 7 quarters since. The position peaked at $1.49M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Graham Capital Management held 42,179 shares of Pacific Biosciences worth $55.7K as of Q1 2026.
Graham Capital Management sold 146,306 Pacific Biosciences shares in Q1 2026, an estimated $262K.
Pacific Biosciences made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1087 holding.
Graham Capital Management first reported a position in Pacific Biosciences in Q1 2021 and has held it in 7 quarters since.
Graham Capital Management's Pacific Biosciences position peaked at $1.49M in Q1 2021.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.